No headlines found.
No press releases found.
No news found.
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry, and other vaccines.
Zhengye Biotechnology Holding Limited - trades on the NASDAQ stock market under the symbol ZYBT.
As of December 31, 2025, ZYBT stock price climbed to $1.15 with 6,749 million shares trading.
ZYBT has a beta of -0.31, meaning it tends to be less sensitive to market movements. ZYBT has a correlation of 0.00 to the broad based SPY ETF.
ZYBT has a market cap of $54.50 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that ZYBT belongs to (by Net Assets): PGJ.
ZYBT support price is $1.05 and resistance is $1.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYBT shares will trade within this expected range on the day.
